Comparable stake leader
FMR LLC
SEC ownership of Scholar Rock Holding Corp
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001727196.
Disclosed value leader
FMR LLC
Comparable rows
6/50
Latest evidence
21 Sep 2026
- Public ticker
- SRRK on Nasdaq
- Parsed ownership sources
-
13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
FMR LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
6 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
FMR LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
21 Sep 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001727196
- Issuer location
- Cambridge, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Scholar Rock Holding Corp (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
6/50
Latest evidence
21 Sep 2026
13F
13D/G
3/4/5
Lead comparable stake: 15%
44 rows are not safely comparable across share classes.
13D/G row: FMR LLC
Showing 1-8 of 50 holder rows.
Quick read
FMR LLC leads the comparable SEC ownership view at 15%.
6 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FMR LLC's linked filing trail.
Comparable ownership
Top 5
FMR LLC
15%
Invus Global Management, LLC
8%
Samsara BioCapital, L.P.
7.2%
WELLINGTON MANAGEMENT GROUP LLP
5.6%
PRICE T ROWE ASSOCIATES INC /MD/
5.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13F
13D/G
Company
|
15%
Reported 13D/G
· 31 Dec 2024
|
$989,738,234
17,995,241 shares
|
— | 30 Jun 2026 |
| Invus Global Management, LLC |
13D/G
3/4/5
Invus Public Equities, L.P. · 10%+ Owner
|
8%
Reported 13D/G
· 30 Jun 2026
|
$526,625,715
9,575,013 shares
|
-$68,750,000 | 30 Jun 2026 |
| Samsara BioCapital, L.P. |
13D/G
Srinivas Akkaraju
|
7.2%
Reported 13D/G
· 03 Oct 2025
|
$260,368,230
6,991,553 shares
|
$0 | 03 Oct 2025 |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
13D/G
Company
|
5.6%
Reported 13D/G
· 31 Dec 2025
|
$369,989,675
6,727,085 shares
|
— | 30 Jun 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
13D/G
Company · T. Rowe Price Associates, Inc.
|
5.4%
Reported 13D/G
· 31 Mar 2026
|
$373,717,000
6,794,837 shares
|
— | 30 Jun 2026 |
| Redmile Group, LLC |
13D/G
13F
Company
|
3.6%
Reported 13D/G
· 30 Jun 2026
|
$237,110,060
4,311,092 shares
|
-$261,554,095 | 30 Jun 2026 |
| Siren, L.L.C. |
13F
3/4/5
Individual · 10%+ Owner
|
—
denominator unverified
|
$526,625,715
9,575,013 shares
|
— | 30 Jun 2026 |
| Invus Public Equities, L.P. |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$385,262,708
9,250,005 shares
|
— | 10 Dec 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$19,442,069.
Buys
$0
Insiders: 0
Sells
$19,442,069
Insiders: 13
Net
-$19,442,069
Shares: -425,572
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 425,572
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 17,149 | $0 | $923,084 | -$923,084 |
| 6-9 | 0 | 117,634 | $0 | $5,674,077 | -$5,674,077 |
| 9-12 | 0 | 290,789 | $0 | $12,844,909 | -$12,844,909 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 27 reporting-owner rows connected to Scholar Rock Holding Corp. Open a relationship link for the CIK-to-CIK filing trail.
Rows
27
Largest Forms 3/4/5 holder
Invus Public Equities, L.P.
Net 12M change
-$19,442,068
Latest report
24 Sep 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Invus Public Equities, L.P. | 10%+ Owner | $385,262,708 | Filing P/S | 10 Dec 2024 | ||
| Srinivas Akkaraju | Director | $340,463,626 | Mixed | 04 Jun 2026 | ||
| Kristina Burow | Director | $135,237,870 | -$164,064 | -0.12% | Mixed | 01 Jul 2026 |
| David Hallal | Chief Executive Officer, Director | $111,499,670 | -$3,970,838 | -3.4% | Mixed | 21 Sep 2026 |
| Samsara BioCapital GP, LLC | 10%+ Owner | $108,133,716 | Mixed | 16 Oct 2023 | ||
| Siren, L.L.C. | 10%+ Owner | $101,166,050 | Mixed | 25 Jul 2024 | ||
| Invus Global Management, LLC | 10%+ Owner | $79,563,845 | Mixed | 11 Dec 2025 | ||
| Keith Woods | Chief Operating Officer | $34,103,025 | -$1,221,706 | -3.5% | Mixed | 24 Sep 2026 |
| Akshay Vaishnaw | President of R&D, Director | $31,258,804 | -$1,479,792 | -4.5% | Filing P/S | 16 Apr 2026 |
| Vikas Sinha | Chief Financial Officer | $30,729,051 | -$1,231,509 | -3.9% | Filing P/S | 16 Apr 2026 |
| Backstrom Jay T. | CHIEF EXECUTIVE OFFICER, Director | $16,062,247 | Mixed | 10 Mar 2025 | ||
| Junlin Ho | General Counsel | $11,238,654 | -$802,273 | -6.7% | Filing P/S | 17 Feb 2026 |
| Caryn Parlavecchio | Chro | $7,867,313 | -$713,935 | -8.3% | Filing P/S | 17 Feb 2026 |
| Nagesh K. Mahanthappa | Interim CEO and President | $7,653,597 | Mixed | 16 Jun 2022 | ||
| Jing L. Marantz | Chief Medical Officer | $5,863,111 | -$451,299 | -7.1% | Filing P/S | 17 Feb 2026 |
| Mo Qatanani | Chief Scientific Officer | $4,772,613 | -$8,603,281 | -64% | Filing P/S | 23 Feb 2026 |
| Yung H. Chyung | Chief Medical Officer | $4,117,505 | Mixed | 14 Feb 2022 | ||
| Edward H. Myles | Coo & Cfo | $3,882,600 | Filing P/S | 10 Mar 2025 | ||
| Michael Gilman | Director | $3,262,065 | -$137,058 | -4% | Filing P/S | 01 Jul 2026 |
| Erin Moore | Interim PFO and PAO | $2,735,994 | Filing P/S | 24 Mar 2025 |
Recent insider transactions for Scholar Rock Holding Corp
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Keith Woods | SRRK | Common Stock | Gift | -7.75% | -48,034 | 572,021 | 24 Sep 2026 | Direct | ||
| David Hallal | SRRK | Common Stock | Gift | -2.24% | -36,652 | 1,602,382 | 21 Sep 2026 | Direct | ||
| Jeffrey S. Flier | SRRK | Common Stock | Sale | -9.88% | $164,490 | $53.88 | -3,053 | 27,856 | 01 Jul 2026 | Direct |
| Michael Gilman | SRRK | Common Stock | Sale | -4.1% | $137,058 | $53.88 | -2,544 | 59,511 | 01 Jul 2026 | Direct |
| Kristina Burow | SRRK | Common Stock | Sale | -2.59% | $164,064 | $53.74 | -3,053 | 114,657 | 01 Jul 2026 | Direct |
| Joshua Reed | SRRK | Common Stock | Sale | -13.5% | $164,067 | $53.74 | -3,053 | 19,518 | 01 Jul 2026 | Direct |
| Katie Peng | SRRK | Common Stock | Sale | -13.7% | $293,405 | $53.88 | -5,446 | 34,301 | 01 Jul 2026 | Direct |
| Jeffrey S. Flier | SRRK | Common Stock | Award | 28.4% | 6,839 | 30,909 | 04 Jun 2026 | Direct | ||
| Jeffrey S. Flier | SRRK | Stock Option (Right to Buy) | Award | 4,310 | 4,310 | 04 Jun 2026 | Direct | |||
| Joshua Reed | SRRK | Common Stock | Award | 43.5% | 6,839 | 22,571 | 04 Jun 2026 | Direct | ||
| Joshua Reed | SRRK | Stock Option (Right to Buy) | Award | 4,310 | 4,310 | 04 Jun 2026 | Direct | |||
| Richard Brudnick | SRRK | Common Stock | Award | 45.4% | 6,839 | 21,896 | 04 Jun 2026 | Direct | ||
| Richard Brudnick | SRRK | Stock Option (Right to Buy) | Award | 4,310 | 4,310 | 04 Jun 2026 | Direct | |||
| Kristina Burow | SRRK | Common Stock | Award | 6.17% | 6,839 | 117,710 | 04 Jun 2026 | Direct | ||
| Kristina Burow | SRRK | Stock Option (Right to Buy) | Award | 4,310 | 4,310 | 04 Jun 2026 | Direct | |||
| Michael Gilman | SRRK | Common Stock | Award | 12.4% | 6,839 | 62,055 | 04 Jun 2026 | Direct | ||
| Michael Gilman | SRRK | Stock Option (Right to Buy) | Award | 4,310 | 4,310 | 04 Jun 2026 | Direct | |||
| Katie Peng | SRRK | Common Stock | Award | 20.8% | 6,839 | 39,747 | 04 Jun 2026 | Direct | ||
| Katie Peng | SRRK | Stock Option (Right to Buy) | Award | 4,310 | 4,310 | 04 Jun 2026 | Direct | |||
| Srinivas Akkaraju | SRRK | Common Stock | Award | 32.4% | 6,839 | 27,971 | 04 Jun 2026 | Direct | ||
| Srinivas Akkaraju | SRRK | Stock Option (Right to Buy) | Award | 4,310 | 4,310 | 04 Jun 2026 | Direct | |||
| Kristina Burow | SRRK | Common Stock | Options Exercise | 426.2% | 89,800 | 110,871 | 23 Apr 2026 | Direct | ||
| Kristina Burow | SRRK | Stock Option (Right to Buy) | Options Exercise | -100% | -89,800 | 0 | 23 Apr 2026 | Direct | ||
| Keith Woods | SRRK | Common Stock | Sale | -1.62% | $506,651 | $49.57 | -10,220 | 620,055 | 16 Apr 2026 | Direct |
| Akshay Vaishnaw | SRRK | Common Stock | Sale | -1.91% | $607,089 | $49.57 | -12,246 | 630,542 | 16 Apr 2026 | Direct |
| Vikas Sinha | SRRK | Common Stock | Sale | -1.65% | $516,071 | $49.57 | -10,410 | 619,856 | 16 Apr 2026 | Direct |
| David Hallal | SRRK | Common Stock | Sale | -1.83% | $1,517,723 | $49.57 | -30,615 | 1,639,034 | 16 Apr 2026 | Direct |
| Mo Qatanani | SRRK | Common Stock | Sale | -7.93% | $399,351 | $47.07 | -8,484 | 98,445 | 23 Feb 2026 | Direct |
| Jing L. Marantz | SRRK | Common Stock | Sale | -3.19% | $193,418 | $46.53 | -4,157 | 126,012 | 17 Feb 2026 | Direct |
| Junlin Ho | SRRK | Common Stock | Sale | -3.81% | $445,740 | $46.53 | -9,580 | 241,545 | 17 Feb 2026 | Direct |
| Caryn Parlavecchio | SRRK | Common Stock | Sale | -5.07% | $420,382 | $46.53 | -9,035 | 169,087 | 17 Feb 2026 | Direct |
| Mo Qatanani | SRRK | Common Stock | Sale | -6.95% | $371,714 | $46.53 | -7,989 | 106,929 | 17 Feb 2026 | Direct |
| Akshay Vaishnaw | SRRK | Common Stock | Award | 7.89% | 47,021 | 642,788 | 09 Feb 2026 | Direct | ||
| Vikas Sinha | SRRK | Common Stock | Award | 8.06% | 47,021 | 630,266 | 09 Feb 2026 | Direct | ||
| Mo Qatanani | SRRK | Common Stock | Award | 34.2% | 29,258 | 114,918 | 09 Feb 2026 | Direct | ||
| Caryn Parlavecchio | SRRK | Common Stock | Award | 19.6% | 29,258 | 178,122 | 09 Feb 2026 | Direct | ||
| Jing L. Marantz | SRRK | Common Stock | Award | 36% | 34,482 | 130,169 | 09 Feb 2026 | Direct | ||
| Junlin Ho | SRRK | Common Stock | Award | 17% | 36,572 | 251,125 | 09 Feb 2026 | Direct | ||
| David Hallal | SRRK | Common Stock | Award | 8.3% | 128,004 | 1,669,649 | 09 Feb 2026 | Direct | ||
| Keith Woods | SRRK | Common Stock | Award | 8.06% | 47,021 | 630,275 | 09 Feb 2026 | Direct | ||
| Mo Qatanani | SRRK | Common Stock | Sale | -14.8% | $695,938 | $46.71 | -14,898 | 85,660 | 22 Jan 2026 | Direct |
| Mo Qatanani | SRRK | Common Stock | Sale | -7.71% | $373,880 | $44.48 | -8,406 | 100,558 | 16 Jan 2026 | Direct |
| Caryn Parlavecchio | SRRK | Common Stock | Sale | -4.25% | $293,553 | $44.48 | -6,600 | 148,864 | 16 Jan 2026 | Direct |
| Jing L. Marantz | SRRK | Common Stock | Sale | -5.71% | $257,882 | $44.48 | -5,798 | 95,687 | 16 Jan 2026 | Direct |
| Junlin Ho | SRRK | Common Stock | Sale | -3.6% | $356,533 | $44.48 | -8,016 | 214,553 | 16 Jan 2026 | Direct |
| Mo Qatanani | SRRK | Common Stock | Sale | -10.7% | $592,611 | $45.20 | -13,112 | 108,964 | 14 Jan 2026 | Direct |
| Mo Qatanani | SRRK | Common Stock | Options Exercise | 12% | 13,112 | 122,076 | 14 Jan 2026 | Direct | ||
| Mo Qatanani | SRRK | Stock Option (Right to Buy) | Options Exercise | -100% | -13,112 | 0 | 14 Jan 2026 | Direct | ||
| Vikas Sinha | SRRK | Common Stock | Sale | -2.79% | $715,438 | $42.70 | -16,755 | 583,245 | 13 Jan 2026 | Direct |
| R. Keith Woods | SRRK | Common Stock | Sale | -2.79% | $715,054 | $42.70 | -16,746 | 583,254 | 13 Jan 2026 | Direct |
* marks a reported price that did not pass the local price check.